RxDoctor Payments Data

John Meigs, MD

Family Medicine · Centreville, ALNPI 1407942733

Payments from drug & device makers

$970in general payments, 2019–2025

Across 51 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$208
  • Novo Nordisk$168
  • Amgen$150
  • GSK$88
  • Dexcom, Inc.$76
  • Astellas Pharma US Inc$67
  • plus $213 from 9 others

What the payments were for

  • Food & beverage$95699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$970 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$6,484
Medicare patients
27
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$63,205
FarxigaDapagliflozin Propanediol54$53,617
OzempicSemaglutide49$51,786
RybelsusSemaglutide24$36,187
InvokanaCanagliflozin26$34,785
RexultiBrexpiprazole26$30,813
XareltoRivaroxaban36$24,269
JardianceEmpagliflozin35$23,543
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$22,857
JanuviaSitagliptin Phosphate12$20,772
MounjaroTirzepatide12$20,705
MyrbetriqMirabegron23$18,785
TrulicityDulaglutide18$17,128
EntrestoSacubitril/Valsartan31$16,618
LinzessLinaclotide14$11,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$168$87,97373 claims
PfizerEliquis$14$63,20574 claims
Johnson & JohnsonInvokana, Xarelto$208$59,05462 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Incruse Ellipta$88$43,437106 claims
Otsuka America Pharmaceutical, Inc.Rexulti$23$30,81326 claims
Astellas Pharma US IncMyrbetriq$67$18,78523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Centreville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →